Lantheus Faces Investor Lawsuits Over Pylarify Product Claims

Lantheus Holdings finds itself at the center of a significant legal challenge as a series of class-action lawsuits allege the company misled investors regarding the commercial prospects of its key product, Pylarify, a prostate cancer imaging agent. The complaints, filed by multiple prominent law firms, accuse the biopharmaceutical firm of securities fraud, creating a critical test for its management and investor relations.

The core allegation is that between February and August 2025, Lantheus issued overly optimistic statements about the growth potential and competitive standing of Pylarify. According to the legal filings, these purported misrepresentations are directly linked to severe stock price declines experienced during that period. The lawsuits point to two specific events that triggered investor losses.

In May 2025, the... Read more...